Full Press Release Details
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET
Event to focus on lead program, Ampligen, for treatment of pancreatic cancer
OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) --AIM ImmunoTech Inc.(NYSE American: AIM)(“AIM” or the “Company”) today announced thatThomas K. Equels, MS JD, Chief Executive Officerof AIM, will participate in aVirtual Investor Closing Bell Eventon Thursday, February 19, 2026, at 4:00 PM ET.
Equels will focus on AIM’s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoingDURIPANC clinical trialin collaboration with AstraZeneca combining Ampligen and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer.
Alive video webcastof the presentation will be available on theEventspage of the Company’s website (aimimmuno.com). A webcast replay will become available two hours following the live presentation and will be accessible for 90 days.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen®(rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.For more information, please visitaimimmuno.comand connect with the Company onX,LinkedIn, andFacebook.